Advice for Pancreas Cancer

[Guest guest]

On 1 Sep 2007 at 15:59, Bob Hurt wrote:

> A dear friend has a cancer tumor on/in her pancreas. Any advice?

> Truly and sincerely,

Hi,

There is a new Cancer Cure.

The best and latest Cancer Cure is reported by New Scientist

Magazine and is DCA or Dichloroacetate.

Safe and works very quickly by restoring proper mitochondria

function in cancer cells which in turn causes apoptosis or natural

cancer cell death.

See article below.

http://www.newscientist.com/article/dn12369-illegal-cancer-drug-

website-shut-down.html

Read original new scientist article below.

This week I removed a large skin cancer using CANSEMA CREAM and

recommend it to those with similar conditions. I now have a large

hole in my face where the tumor was, which will heal over the coming

weeks.

regards,

moonbeam

Cheap, 'safe' drug kills most cancers

* 20 January 2007

* NewScientist.com news service

* Andy Coghlan

Killing cancer

New Scientist* has received an unprecedented amount of interest in

this story from readers. If you would like up-to-date information on

any plans for clinical trials of DCA in patients with cancer, or

would like to donate towards a fund for such trials, please visit the

site set up by the University of Alberta and the Alberta Cancer Board

< http://www.depmed.ualberta.ca/dca>. We will also follow events

closely and will report any progress as it happens./

IT SOUNDS almost too good to be true: a cheap and simple drug that

kills almost all cancers by switching off their " immortality " . The

drug, dichloroacetate (DCA), has already been used for years to treat

rare metabolic disorders and so is known to be relatively safe. It

also has no patent, meaning it could be manufactured for a fraction

of the cost of newly developed drugs.

Evangelos Michelakis of the University of Alberta in Edmonton,

Canada, and his colleagues tested DCA on human cells cultured outside

the body and found that it killed lung, breast and brain cancer

cells, but not healthy cells. Tumours in rats deliberately infected

with human cancer also shrank drastically when they were fed DCA-

laced water for several weeks.

DCA attacks a unique feature of cancer cells: the fact that they make

their energy throughout the main body of the cell, rather than in

distinct organelles called mitochondria. This process, called

glycolysis, is inefficient and uses up vast amounts of sugar. Until

now it had been assumed that cancer cells used glycolysis because

their mitochondria were irreparably damaged. However, Michelakis's

experiments prove this is not the case, because DCA reawakened the

mitochondria in cancer cells. The cells then withered and died

(/Cancer Cell/, DOI: 10.1016/j.ccr.2006.10.020).

Michelakis suggests that the switch to glycolysis as an energy source

occurs when cells in the middle of an abnormal but benign lump don't

get enough oxygen for their mitochondria to work properly (see

Diagram). In order to survive, they switch off their mitochondria and

start producing energy through glycolysis.

Crucially, though, mitochondria do another job in cells: they

activate apoptosis, the process by which abnormal cells self-

destruct. When cells switch mitochondria off, they become " immortal " ,

outliving other cells in the tumour and so becoming dominant. Once

reawakened by DCA, mitochondria reactivate apoptosis and order the

abnormal cells to die.

?Once reawakened by DCA, mitochondria order the abnormal cancer cells

in a tumour to die?

" The results are intriguing because they point to a critical role

that mitochondria play: they impart a unique trait to cancer cells

that can be exploited for cancer therapy, " says Dario Altieri,

director of the University of Massachusetts Cancer Center in

Worcester.

The phenomenon might also explain how secondary cancers form.

Glycolysis generates lactic acid, which can break down the collagen

matrix holding cells together. This means abnormal cells can be

released and float to other parts of the body, where they seed new

tumours.

DCA can cause pain, numbness and gait disturbances in some patients,

but this may be a price worth paying if it turns out to be effective

against all cancers. The next step is to run clinical trials of DCA

in people with cancer. These may have to be funded by charities,

universities and governments: pharmaceutical companies are unlikely

to pay because they can't make money on unpatented medicines. The pay-

off is that if DCA does work, it will be easy to manufacture and dirt

cheap.

e, a cancer cell biologist at the University of Dundee in

the UK, says the findings challenge the current assumption that

mutations, not metabolism, spark off cancers. " The question is: which

comes first? " he says.

From issue 2587 of New Scientist magazine, 20 January 2007, page 13

regards

moonbeam